MedTrace Logo

CP-690-550 Ointment For Chronic Plaque Psoriasis

NCT01246583 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2021-01-11

Study results available
· View outcomes & findings →

Summary

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

Conditions

Interventions

DRUG

CP-690,550 Ointment 1

2% CP-690,550 Ointment 1 twice daily for 4 weeks

DRUG

Vehicle 1

Vehicle 1 twice daily for 4 weeks

DRUG

CP-690,550 Ointment 2

2% CP-690,550 Ointment 2 twice daily for 4 weeks

DRUG

Vehicle 2

Vehicle 2 twice daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-16
Primary Completion
2011-11-29
Completion
2011-11-29

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246583 on ClinicalTrials.gov